Christina Lorish v. Sun Pharmaceutical Industries Inc.

CourtDistrict Court, D. New Jersey
DecidedMay 27, 2026
Docket3:25-cv-15437
StatusUnknown

This text of Christina Lorish v. Sun Pharmaceutical Industries Inc. (Christina Lorish v. Sun Pharmaceutical Industries Inc.) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Christina Lorish v. Sun Pharmaceutical Industries Inc., (D.N.J. 2026).

Opinion

NOT FOR PUBLICATION UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

CHRISTINA LORISH, Plaintiff, Civil Action No. 25-15437 (MAS) (JBD) V. MEMORANDUM OPINION SUN PHARMACEUTICAL INDUSTRIES INC., Defendant.

SHIPP, District Judge This matter comes before the Court upon Defendant Sun Pharmaceutical Industries, Inc.’s! (“Defendant”) Motion to Dismiss (ECF No. 4) Plaintiff Christina Lorish’s (“Plaintiff”) Complaint (ECF No. 1-1). Plaintiff opposed (ECF No. 10), and Defendant replied (ECF No. 11). The Court has carefully considered the parties’ submissions and reaches its decision without oral argument under Local Civil Rule 78.1(b). For the reasons below, Defendant’s Motion to Dismiss is granted. IL BACKGROUND A. Factual Background Plaintiff, a fifty-nine-year-old individual residing in North Carolina, has worked in the pharmaceutical industry since 1995. (Compl. 1, 5, ECF No. 1-1.) Defendant is a foreign

' The entity was incorrectly pled as “Sun Pharmaceuticals Industries Inc.” (Def.’s Moving Br. 1, ECF No. 4-1.) For the purpose of considering the instant motion, the Court accepts all factual allegations in the Complaint as true. See Phillips v. County of Allegheny, 515 F.3d 224, 228 (3d Cir. 2008).

for-profit corporation with its principal place of business in Princeton, New Jersey. Ud. 42.) Defendant hired Plaintiff in January 2021 as an “Oncology Account Manager.” (/d. § 6.) Throughout her three and a half years of employment with Defendant, “Plaintiff consistently received positive feedback from management, including, among other things, performance evaluations rated ‘Exceptional’ and ‘Exceeds Expectations.’” (/d. § 7.) “Plaintiff was [also] [r]anked first of [twenty-four] individuals” and received “back-to-back Circle of Excellence Awards in 2023 and 2024.” Ud. ¥ 8.) In July 2023, Plaintiff was the only representative to be promoted to a Senior Oncology Account Manager role. Ud. 9.) On April 1, 2024, Plaintiff was directed to begin reporting to Michelle Hirschl, KAD (“Hirschl”).3 Ud. $ 10.) One week later, on April 8, 2024, Plaintiff tripped and injured her foot, resulting in a formal diagnosis of “contusion of the left foot.” Ud. § 13.) Plaintiff's discharge orders stated, in relevant part, that “[Plaintiff] may continue primarily seated work with the ability to elevate foot as needed for two weeks. Please allow patient to attend meetings virtually.” Ud. J 14.) Despite these restrictions, Plaintiff participated in a formal face-to-face introductory meeting with Hirschl. Ud. § 15.) During this meeting, “Hirschl stated that she refused to acknowledge or heed Plaintiff's work restrictions and directed Plaintiff to attend the National Fast Start Meeting in Chicago, Ilinois[,] from April 15 to 19, 2024[,] and that no virtual meeting options would be made available.” Ud. 16.) Plaintiff advised Alison Cho (“Cho”), Defendant’s Human Resources Manager, of Hirschl’s refusal to provide accommodations for Plaintiff, but “Cho failed and refused to engage in a back-and-forth dialogue with Plaintiff’ regarding her needed accommodations. (/d. 17, 18.)

Plaintiff believes that Hirschl “has a reputation of discrimination (by way of, among other things, termination) against female employees, which included at least five other employees” of Defendant. (Compl. § 11.)

Rather, “Cho directed Plaintiff to use vacation days to ‘cover’ any ‘time off.’” (Ud. 4 19.) Defendant also “denied [Plaintiff] from taking short-term disability as a result of her injury” and refused to let Plaintiff take meetings virtually in accordance with her discharge orders. (Jd. qq 20, 21.) Prior to terminating Plaintiff, “Hirsch! solicited information from Plaintiff's former manager and colleagues] concerning her personality, work-ethic, and collaboration/communication skills[,]” but failed to disclose to Plaintiff that she was being investigated. (id. §§ 22, 23.) Defendant “subjected Plaintiff to unstructured interviews by management and colleagues for the sole purpose of providing character assessments to Hirschl.” Ud. 24.) Additionally, from May 21 to 23, 2024, Hirschl accompanied Plaintiff on a “field ride” to allegedly “observ[e] Plaintiff's interactions with providers and to provide feedback[] concerning business planning, product and scientific knowledge, and time management.” (/d. J 25.) According to Plaintiff, the “field ride” “was a sham and a thinly-veiled scheme orchestrated by Hirschl to provide a manufactured basis for terminating Plaintiff's employment.” (/d. J 26.) During the “field ride,” Hirschl “fabricated pretexts” and “falsely claimed that Plaintiff was unprepared, unfamiliar with her accounts, and unable to recall significant information about the accounts and territory.” Ud. 29, 30.) Ultimately, Plaintiff's performance during the “field ride” was rated as “needs improvement” even though there were “no written or verbal communications from Plaintiff's assigned Health Care Providers ([‘]HCP[’]) in her territory to support it.” Ud. ¥ 28.)

“Throughout Plaintiff’s entire [thirty ]-plus year career, she never received a ‘needs improvement’ rating” before this. (Compl. { 27.) > Hirsch] also accused Plaintiff of “not being aware of an HCP’s relocation to a new office[,]” even though “Plaintiff actually advised Hirschl of said HCP’s relocation.” (Compl. {§ 31, 32.)

Hirschl then directed Plaintiff to reclassify previously-approved administrative office days as paid time off (the “PTO”) and/or vacation days going back to January 1, 2024. Ud. § 32.) Plaintiff complied with the directive out of fear of retaliation. Ud. J 34.) Defendant subsequently: (1) “accused [Plaintiff] of falsifying documentation[] concerning HCP visits, ‘Cash’ reimbursements, and reimbursement of non-business expenses” even though Hirschl directed Plaintiff and other similarly-situated employees to document expenses in such a manner; (2) failed to investigate, discipline, and/or terminate other similarly-situated employees for similar conduct; and (3) failed to provide Plaintiff with a performance improvement plan over alleged concerns with Plaintiff's performance. Ud. J¥ 35, 36, 37.) Moreover, Defendant failed to pay Plaintiff for: (1) unused PTO or compelled Plaintiff to use PTO for business-related travel; (2) a 2023-2024 Circle of Excellence Award trip to Aruba; and (3) 2024 vested commissions. (/d. 38.) Less than two months after Plaintiff began reporting to Hirschl, Defendant refused to promote Plaintiff despite her qualifications, instead terminating Plaintiff and replacing Plaintiff with “an individual half her age.” Ud. 4, 12, 39.) B. Procedural Background In August 2025, Plaintiff initially brought this case in the Superior Court of New Jersey, Mercer County, and Defendant subsequently removed to this Court. (See generally Not. of Removal, ECF No. 1.) Plaintiff's Complaint asserts five causes of action: (1) violation of Title VII of the Civil Rights Act (“Title VIZ’) (‘Count One”); (2) violation of the Age Discrimination in Employment Act (the “ADEA”) (“Count Two”); (3) violation of Title I of the Americans with Disabilities Act (the “ADA”) (‘Count Three”); (4) violation of the New Jersey Law Against Discrimination (the “NJLAD”) (“Count Four”); and (5) promissory estoppel (“Count Five”). (See Compl. {| 40-69.) On October 12, 2025, Defendant moved to dismiss the Complaint in its entirety.

(See generally Mot. to Dismiss, ECF No. 4.) Plaintiff opposed (see generally P1.’s Opp’n Br., ECF No. 10) and Defendant replied (see generally Def.’s Reply Br., ECF No. 11). Il. LEGAL STANDARD Federal Rule of Civil Procedure

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Conley v. Gibson
355 U.S. 41 (Supreme Court, 1957)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Karen Malleus v. John George
641 F.3d 560 (Third Circuit, 2011)
Phillips v. County of Allegheny
515 F.3d 224 (Third Circuit, 2008)
Fowler v. UPMC SHADYSIDE
578 F.3d 203 (Third Circuit, 2009)
Peikin v. Kimmel & Silverman, P.C.
576 F. Supp. 2d 654 (D. New Jersey, 2008)
Anthony Hildebrand v. Allegheny County
757 F.3d 99 (Third Circuit, 2014)
Borough of West Mifflin v. Lancaster
45 F.3d 780 (Third Circuit, 1995)
Phillips v. Sheraton Society Hill
163 F. App'x 93 (Third Circuit, 2005)
Foster v. JLG Industries, Inc.
199 F. App'x 90 (Third Circuit, 2006)
Jane Doe v. Mercy Catholic Medical Center
850 F.3d 545 (Third Circuit, 2017)
John Doe v. University of the Sciences
961 F.3d 203 (Third Circuit, 2020)
Pennsylvania ex rel. Zimmerman v. Pepsico, Inc.
836 F.2d 173 (Third Circuit, 1988)
Kehr Packages, Inc. v. Fidelcor, Inc.
926 F.2d 1406 (Third Circuit, 1991)

Cite This Page — Counsel Stack

Bluebook (online)
Christina Lorish v. Sun Pharmaceutical Industries Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/christina-lorish-v-sun-pharmaceutical-industries-inc-njd-2026.